Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2022-04-04 Regulatory Filings
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
ERYTECH présentera une nouvelle approche de vésiculation au 24ème congrès de la Société Européenne des Globules Rouges (ERCS)
Regulatory Filings Classification · 1% confidence The document is a press release dated April 4, 2022, announcing that ERYTECH Pharma will present new data regarding its ERYCEVTM approach at the 24th European Red Cell Society (ERCS) congress. The text details the presentation topic, date, and context, and includes standard company boilerplate information, forward-looking statements, and contact details. This type of announcement, focusing on participation in a scientific conference and presentation of research findings, is characteristic of an Investor Presentation (IP) or a general press release related to investor/scientific updates. Since it is an announcement about presenting data at a congress, and not the presentation slides themselves (IP) or a formal financial report (10-K, IR, ER), it fits best under a category related to investor communication or scientific updates. Given the options, it is a communication intended for investors and the scientific community about upcoming data presentation, which aligns closely with the purpose of an Investor Presentation (IP) or a general Regulatory Filing (RNS) if no better fit exists. However, since it is a detailed announcement about specific scientific data being presented, it is more specific than a generic RNS. It is not a formal financial report, earnings release, or proxy statement. It is an announcement of scientific/research progress, which often accompanies or precedes an Investor Presentation. Given the content focuses on presenting data at a scientific congress, 'Investor Presentation' (IP) is a plausible fit if the content is substantive, but since it is an *announcement* of a presentation, and not the presentation itself, 'Regulatory Filings' (RNS) serves as a strong general category for press releases detailing scientific milestones or conference participation that don't fit other specific categories like ER or IR. Given the context of presenting scientific data, and the lack of a specific 'Scientific Update' category, RNS is the safest fallback for a press release detailing conference participation, although IP is conceptually close if the content were the slides themselves. I will classify it as RNS as it is a general press release about a corporate/scientific event.
2022-04-04 French
ERYTECH annonce sa participation à des conférences investisseurs en avril
Report Publication Announcement Classification · 1% confidence The document is a press release from ERYTECH Pharma announcing the participation of its CEO and CFO in upcoming investor conferences in April 2022 (Investor Access Event and KEMPEN 14th Life Sciences Conference). It details the dates, locations, and participating executives, and invites investors to schedule one-on-one meetings. This type of announcement, which informs the market about management's schedule for meeting with investors, is best classified as an Investor Presentation or related activity announcement, but given the specific definitions, it most closely aligns with an announcement related to investor engagement. Since it is not a formal report (10-K, IR, ER) nor a specific transaction notice (DIV, DIRS, POS), and it is an announcement about accessing investors, it fits best under Investor Presentation (IP) if it were a presentation deck, or more generally, as a communication aimed at investors. However, looking at the definitions, this is an announcement about management's schedule for investor meetings, which is a common precursor or component of investor relations activities. Since there is no specific code for 'Investor Meeting Schedule Announcement', and the content is focused on management access and company pipeline updates (which often accompany such meetings), it is a form of Investor Presentation/Access communication. Given the options, 'IP' (Investor Presentation) is the closest fit for proactive investor communication detailing management availability and company updates, although 'RPA' (Report Publication Announcement) or 'RNS' (Regulatory Filings) are possibilities if it were purely administrative. Because it details *access* to management and company information for investors, 'IP' is the most appropriate classification for this type of proactive investor relations material.
2022-03-28 French
ERYTECH to Participate in the Upcoming April Investor Conferences
Investor Presentation Classification · 1% confidence The document is a press release from ERYTECH Pharma announcing its participation in upcoming investor conferences in April 2022. It lists the specific events (INVESTOR ACCESS Event, KEMPEN 14th Life Sciences Conference), dates, locations, and attending executives. This type of announcement, which details planned investor outreach and meetings rather than releasing financial results, management changes, or regulatory filings, is best classified as an Investor Presentation or related communication, although it is not a formal presentation document itself. Given the options, this announcement is directly related to investor relations activities and scheduling. Since there is no specific code for 'Investor Conference Schedule Announcement', we must choose the closest fit. 'Investor Presentation' (IP) is for the presentation materials themselves. 'Earnings Release' (ER) is incorrect. 'Regulatory Filing' (RNS) is too general. Since the core purpose is to inform investors about upcoming access opportunities, and it is a brief announcement, it most closely aligns with general investor communication. However, in the context of financial reporting categories, announcements about management meeting investors at conferences often accompany or precede formal presentations or earnings calls. Given the content focuses entirely on scheduling meetings at investor events, it is a form of investor outreach communication. If we strictly follow the definitions, none fit perfectly. However, 'Investor Presentation' (IP) is the category dealing with investor-facing materials. Since this is an announcement *about* investor access, and not a formal report, it is often grouped with investor communications. Given the short length (3842 chars) and the nature of announcing participation, it is not a full report. If we must choose from the list, and recognizing this is an announcement about investor engagement, 'Investor Presentation' (IP) is the most contextually relevant category for investor-focused scheduling, although 'RNS' (Regulatory Filings) could be a fallback. I will classify it as 'IP' as it is a direct communication aimed at facilitating investor engagement, which is the primary function of an Investor Presentation package, even if this specific document is just the schedule.
2022-03-28 English
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021
Earnings Release Classification · 1% confidence The document is titled "ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021" and contains detailed operational updates, clinical trial progress, and year-end financial figures (cash position as of December 31, 2021). It explicitly mentions postponing the reporting of FY2021 financial results to April, suggesting this document serves as a preliminary update or highlights package preceding the full annual filing. The content structure—business highlights, financial update, and forward-looking milestones—is characteristic of an Earnings Release (ER) or a comprehensive quarterly/annual update that precedes the formal 10-K. Since it covers the full year (FY2021) and provides key financial metrics and business narrative, it aligns best with an Earnings Release (ER), which typically precedes the full 10-K filing. It is not a transcript (CT), a formal audit report (AR), or a proxy statement (DEF 14A/PSI). Given the focus on Q4 and Full Year results, ER is the most appropriate classification for this type of press release. Q4 2021
2022-03-11 English
ERYTECH fait le point sur ses activités et publie sa position de trésorerie pour l’exercice 2021
Management Reports Classification · 1% confidence The document is titled "ERYTECH fait le point sur ses activités et publie sa position de trésorerie pour l'exercice 2021" (ERYTECH provides an update on its activities and publishes its cash position for the 2021 fiscal year). It details clinical trial progress, strategic alternatives, and specifically reports the cash position as of December 31, 2021. Crucially, it mentions that due to the need to publish *proforma* accounts related to strategic discussions, the company is postponing the publication of its full 2021 financial results to a later date in April. This document serves as a comprehensive operational and financial update covering the full year, but it is not the final, audited Annual Report (10-K) or a standard quarterly report (IR). It strongly resembles a detailed management discussion and analysis (MDA) or a comprehensive update often released around the time of the Annual Report, but specifically focusing on operational milestones and cash position, often preceding the full financial statements. Given the detailed operational review, clinical updates, and the specific focus on the year-end cash position, it aligns best with a Management Report (MDA) which provides management's explanation of results and outlook, especially since the formal financial results publication is delayed. It is not a short announcement (RPA) as it is quite lengthy and detailed.
2022-03-11 French
Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2022
Share Issue/Capital Change Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2022." It explicitly references Article 223-16 of the French AMF regulation and provides a table detailing the total number of shares and voting rights as of the end of February 2022, comparing it to previous months. This type of regular disclosure regarding the total share capital and voting rights structure is a specific regulatory requirement, often falling under general regulatory announcements or specific capital structure updates. Given the options, it is not a full Annual Report (10-K), Earnings Release (ER), or Interim Report (IR). It is a specific disclosure about the composition of the share capital and voting rights. While it relates to capital structure, it is a mandatory monthly disclosure rather than a financing event (CAP) or a director's dealing (DIRS). Since it is a specific regulatory disclosure that doesn't fit perfectly into the other defined categories (like DEF 14A for voting results or DIV for dividends), the most appropriate classification is the general regulatory filing fallback, RNS, as it is a mandatory monthly regulatory update.
2022-03-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.